238
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Effect of gal/GalNAc regioisomerism in galactosylated liposomes on asialoglycoprotein receptor-mediated hepatocyte-selective targeting in vivo

, , , , , , & show all
Pages 79-89 | Received 26 Jul 2019, Accepted 14 Oct 2019, Published online: 06 Nov 2019

References

  • Bally, M.B., et al., 1990. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochimica et biophysica acta (BBA) - biomembranes, 1023(1), 133.
  • Bernardes, G.J., et al., 2010. Design, synthesis and biological evaluation of carbohydrate-functionalized cyclodextrins and liposomes for hepatocyte-specific targeting. Organic and biomolecular chemistry, 8(21), 4987–4996.
  • Biessen, E.A., et al., 1994. Cholesterol derivative of a new triantennary cluster galactoside directs low- and high-density lipoproteins to the parenchymal liver cell. Biochemical journal, 302(1), 1), 283.
  • Bray, F., et al., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394–424.
  • Chopineau, J., et al., 1988. Production of biosurfactants from sugar alcohols and vegetable oils catalyzed by lipases in a nonaqueous medium. Biotechnology and bioengineering, 31(3), 208–214.
  • Dube, D., et al., 2010. Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin. Drug development and industrial pharmacy, 36(5), 547–555.
  • E Silva, A.T.M., et al., 2018. Synthesis of cholesterol-based neoglycoconjugates and their use in the preparation of liposomes for active liver targeting. Carbohydrate research, 465, 52–57.
  • Gupta, S., et al., 2013. Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir. Drug development and industrial pharmacy, 39(12), 1866.
  • Halldorsson, A., et al., 2001. Chemoenzymatic synthesis of structured triacylglycerols. Tetrahedron letters, 42(43), 7675–7677.
  • Hattori, Y., et al., 2000. Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting. Journal of controlled release, 69(3), 369–377.
  • Huang, X., et al., 2017. Well-Defined Multivalent Ligands for Hepatocytes Targeting via Asialoglycoprotein Receptor. Bioconjugate chemistry, 28(2), 283–295.
  • Khorev, O., et al., 2008. Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorganic and medicinal chemistry, 16(9), 5216–5231.
  • Kinberger, G.A., et al., 2016. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. Bioorganic and medicinal chemistry letters, 26(15), 3690–3693.
  • Kolatkar, A.R. and Weis, W.I., 1996. Structural basis of galactose recognition by C-type animal lectins. Journal of biological chemistry, 271(12), 6679–6685.
  • Luo, L.H., et al., 2016. Pharmacokinetics and tissue distribution of docetaxel liposome mediated by a novel galactosylated cholesterol derivatives synthesized by lipase-catalyzed esterification in non-aqueous phase. Drug delivery, 23(4), 1282–1290.
  • Managit, C., et al., 2005a. Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. Journal of pharmaceutical sciences, 94(10), 2266–2275.
  • Managit, C., et al., 2005b. Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. International journal of pharmaceutics, 301(1–2), 255–261.
  • Miura, Y., et al., 2003. Chemoenzymatically synthesized glycoconjugate polymers. Biomacromolecules, 4(2), 410–415.
  • Nie, H., et al., 2015a. Lipase-catalyzed synthesis of novel galactosylated cholesterol. Chinese chemical letters, 26(5), 543–546.
  • Nie, H., et al., 2015b. Optimization of lipase-catalyzed synthesis of novel galactosyl ligands for selective targeting of liposomes to the asialoglycoprotein receptor. Biocatalysis and biotransformation, 33(2), 130–139.
  • Pathak, P.O., et al., 2015. Cholesterol anchored arabinogalactan for asialoglycoprotein receptor targeting: synthesis, characterization, and proof of concept of hepatospecific delivery. Carbohydrate research, 408, 33–43.
  • Pranatharthiharan, S., et al., 2017. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma. Drug delivery, 24(1), 20.
  • Rensen, P.C., et al., 2001. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. Journal of biological chemistry, 276(40), 37577–37584.
  • Rieder, H., et al., 1992. Functional spectrum of sinusoidal endothelial liver cells: Filtration, endocytosis, synthetic capacities and intercellular communication. Journal of hepatology, 15(1–2), 237–250.
  • Rozema, D.B., et al., 2007. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 104(32), 12982–12987.
  • Schlepperschäfer, J., et al., 1986. Endocytosis via galactose receptors in vivo: Ligand size directs uptake by hepatocytes and/or liver macrophages. Experimental cell research, 165(2), 494–506.
  • Sun, P., et al., 2014. Glyco-regioisomerism Effect on Lectin-Binding and Cell-Uptake Pathway of Glycopolymer-Containing Nanoparticles. ACS macro letters, 3(1), 96–101.
  • Wang, S.L., et al., 2008. Design and synthesis of novel galactosylated polymers for liposomes as gene drug carriers targeting the hepatic asialoglycoprotein receptor. Journal of drug targeting, 16(3), 233–242.
  • Wang, S.N., et al., 2006. Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. European journal of pharmaceutics and biopharmaceutics, 62(1), 32–38.
  • Wu, A.M., et al., 2006. Recognition factors of Ricinus communis agglutinin 1 (RCA(1)). Molecular immunology, 43(10), 1700–1715.
  • Xia, Y., et al., 2019. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma. Drug delivery, 26(1), 1–11.
  • Xue, Y., et al., 2010. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. Journal of controlled release official journal of ease, 141(2), 183–192.
  • Yamamoto, M., et al., 2000. Utility of liposomes coated with polysaccharide bearing 1-amino-lactose as targeting chemotherapy for AH66 hepatoma cells. Oncology reports, 7(1), 107–111.
  • Yu, F., et al., 2007. Galactosylated liposomes as oligodeoxynucleotides carrier for hepatocyte-selective targeting. Pharmazie, 62(7), 528–533.
  • Zelensky, A.N. and Gready, J.E., 2005. The C-type lectin-like domain superfamily. FEBS journal, 272(24), 6179–6217.
  • Zhang, H., et al., 2015. Novel Galactosylated Poly(ethylene glycol)-Cholesterol for Liposomes as a Drug Carrier for Hepatocyte-Targeting. Journal of nanoscience and nanotechnology, 15(6), 4058–4069.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.